Bovine papillomavirus type 1 (BPV-1) virions were produced in vitro using vaccinia virus (VV) recombinants expressing the BPV-I L1 and L2 capsid proteins. Particles morphologically resembling papillomaviruses were observed in the nucleus of cells infected with a W recombinant for the BPV-1 L1 protein, and greater numbers of similar particles were seen in the nuclei of cells infected with a VV double recombinant for L1 and L2. Virus-like particles (VLPs) assembled in cells infected with the VV double recombinant for BPV-1 L1 and L2, and not those assembled in ceils infected with the VV recombinant for BPV-1 L1 alone, were able to package BPV-1 DNA. Transcription of the BPV-1 E1 viral open reading frame was observed after a mouse fibroblast cell line was exposed to VLPs produced using a BPV-1 L1/L2 VV recombinant in a cell line containing episomal BPV-1 DNA. E1 transcription was not observed when the VLPs were pre-incubated with antibodies to the capsid protein of BPV-1. This system should allow an in vitro approach to the definition of the BPV-1 cellular receptor.
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Papillomaviruses (PVs) infect epithelial cells, and such infection may lead to neoplastic transformation Zachow et al., 1982; Lacey et al., 1986; Pater et al., 1988; zur Hausen, 1991) . The molecular basis of PV-induced epithelial cell transformation is at least partially understood (Gissmann, 1992; Pater et al., 1988; Yang et al., 1985) , but the mechanism of infection of epithelial cells by PV virions and the basis of host resistance to PV infection remain unknown. This is largely because there is no in vitro system permissive for vegetative PV infection, although partial demonstration of the reproductive cycles of human papillomavirus types 11 and 33 (HPV-11 and -33) has now been achieved in in vitro raft culture (Meyers et al., 1992; Dollard et al., 1992) . We have shown, using vaccinia virus (W) recombinants expressing the L1 and L2 capsid proteins of HPV type 16 (HPV-16), that particles resembling papillomavirus capsids can be produced in vitro (Zhou et al., 1991) . CV-1 cells infected with a VV double recombinant for the L1 and L2 open reading frames (ORFs) of HPV-16 produced virus-like particles (VLPs; Zhou et al., 1991) , with capsomeres similar in appearance to those seen in HPV-1 and bovine PV type 1 (BPV-1) particles purified from clinical lesions (Baker et al., 1991 ; Staquet et al., 1981) . However, the morphology of the HPV-16 VLPs was different to naturally occurring HPV-1 and BPV-1 particles. As natural HPV-16 virions have not been purified from clinical lesions, we wished to determine whether this morphological difference was a property of HPV-16, or of the recombinant VV system used to produce the virions.
We chose to study BPV-1 particles, because natural particles have been characterized morphologically and immunologically (Chen et al., 1982; Baker et al., 1991; Cowsert et al., 1987) , and cell lines are available which are permissive for the episomal replication of BPV-1 DNA (Law et al., 1981) . We therefore made a VV double recombinant for the L1 and L2 capsid proteins of BPV-1 (Fig. 1) . BPV-1 L1 was expressed from the natural VV late promoter (4b) and L2 from a synthetic VV late promoter (p480) (Zhou et al., 1991) . The Escherichia coli gpt gene (Falkner & Moss, 1988) was used as the selection marker. The BPV-1 L1 and L2 genes were cloned by PCR from plasmid pml-1 (Lusky & Botchan, 1985) . As the BPV-1 genome is linearized and cloned into this plasmid at a BamHI site in the BPV-1 L20RF, the BPV-1 genome was first isolated from pml-1 by BamHI digestion and recircularized, and the circularized BPV-1 DNA was used as the PCR template. Oligonucleotide primers used for L1 amplification were: 5' CGGGAT-__CATGGCGTTGTGGCAACAAGGCCAGA AGCTG and 5' CGGGATCCTTATTTTTTTTTTTTTTTTGC-AGGCTTACTGG. The BamHI site is underlined and the first methionine and stop codons are in bold. Oligonucleotide primers for L2 amplification were: 5' GCAGATCTATGAGTGCACGAAAAAGAGTAAA-ACGTGCCAGTG and 5' GCAGATCTTTAGGC-ATGTTTCCGTTTTTTTCGTTTCC. The BgllI sites are underlined and the first methionine and stop codons are in bold. The amplified 1478 bp L1 fragment was cloned into the BamHI site in plasmid RK19 (Kent, 1988) to produce RK19BPVL1. The L1 gene and VV 4b promoter were isolated from this plasmid by digestion with MluI and Sinai and transferred into plasmid pSX3 (Zhou et al., 1990 ) to produce pSXBPVL1. The 1409 bp L2 fragment was digested with BgllI and cloned into the BamHI site in plasmid p480 (Zhou et al., 1991) to produce p480BPVL2. The synthetic VV late promoter and BPV L2 gene were cloned from this plasmid into the SmaI site in pSXBPVL1 to produce the double recombinant plasmid pSXBPVL1L2. Transfection of pSXBPVL1 or pSXBPVLIL2 DNA into monolayers of CV-1 cells infected with wild-type (wt) VV strain WR resulted in the VV recombinants pSXBPVL1VV (L 1-expressing) and pSXBPVL1L2VV (L1-and L2-expressing). Infection of cells with BPV-1 L1-and L2-expressing VV double recombinants resulted in the accumulation of VLPs in the cell nucleus (Fig. 2a) , and these resembled authentic HPV-I and BPV-1 virions more closely than the HPV-16 particles we have previously described (Zhou et al., 1991) , in that the particles were uniform in size, and showed clearer icosahedral symmetry. Cells infected with the BPV-1 L1 and L2 VV recombinant expressed BPV-1 L1 protein (Fig. 3a) and L2 mRNA (Fig. 3b) . L1 protein was detected by immunoprecipitation and Western blotting (Zhou et al., 1991) with rabbit anti-BPV-1 antibody (Dako) at a 1000-fold dilution. BPV-1 L2 mRNA was detected in total RNA extracted from cells and purified by centrifugation through CsCI as described previously (Zhou et al., 1991) . Total RNA, 10 lag per lane, was run on 1"2 % formaldehyde-agarose gels, transferred to nylon membranes, and probed with a 3~P-labelled BPV-1 L2 gene.
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Icosahedral 50 nm VLPs of apparently authentic morphology could be purified from L1 and L2 W recombinant-infected cells (Fig. 2 c) . VLPs were isolated and purified by density gradient centrifugation as previously described (Zhou et al., 1991) . Our previous work with HPV-16 had shown that both L1 and L2 proteins were required for the assembly of HPV-16 VLPs (Zhou et al., 1991) , which contrasts with the observation that, for parvovirus (Kajigaya et al., 1991) , bluetongue virus (Loudon et al., 1991) and polyoma virus (Salunke et al., 1986) , VLPs assemble in cells when the major capsid protein alone is expressed as a recombinant protein. We therefore produced a VV recombinant for BPV-1 L1 (Fig. 1) and observed that when cells were infected with this VV recombinant, VLPs of similar morphology to those obtained with the L1/L2 VV double recombinant could be observed in the cell nucleus (Fig. 2 b) , and purified by density gradient centrifugation (Fig. 2d) , although the number of particles per cell nucleus was considerably lower than with the L1/L2 W recombinant, and there was an accumulation of amorphous electron-dense material in the nuclei of cells infected with this construct, similar to that observed with HPV-16 L1 and L2 recombinant baculovirus-infected ceils (Xi & Banks, 1991) . HPV-16 is thus different from BPV-1 in its requirements for capsid assembly, and the lack of morphologically authentic PV virions in cells infected with the HPV-16 L1/L2 VV recombinant and the lack of PV virions seen in HPV-16-infected tissue by electron microscopy (Schneider, 1987) suggests that HPV-16, in contrast to other PVs, may be relatively inefficient in viral capsid formation.
A minority of VLPs from cells infected with the BPV-1 L1/L2 VV recombinant had electron-dense cores (Fig.  2 c) suggesting that these might contain DNA. Electrondense particle cores were observed with CON/BPV. B2 ceils (Fig. 2c, inset) , which contain 50 episomal copies of BPV-1 DNA, but also with CV-1 cells, where any packaged DNA was presumably of cellular origin. Such electron-dense material was not seen in the particles from cells infected with L1 VV recombinant contained barely detectable BPV-1 DNA (Fig. 4a ). Viral DNA from VLPs was predominantly in linear form. We surmise that L2 may be necessary for the efficient packaging of the BPV-1 episome in the VLPs. Titration in a Southern blot of particles purified from L1/L2 VV recombinantinfected B2 cells, using purified BPV-1 DNA as a standard, showed that approximately two to three BPV-1 genomic equivalents were recovered per infected B2 cell (data not shown). This contrasts with the high numbers of complete particles seen in the L 1/L2 VV recombinantinfected B2 cell nuclei by electron microscopy, and suggests that the ratio of defective to complete particles produced by this system may be high.
To establish whether the apparently complete BPV-1 virions were infectious for BPV-l-permissive cells in vitro, we used monolayers of C127 cells, which have previously been used to assay titres of infectious naturally occurring BPV-1 particles in vitro by enumeration of foci of transformed cells . CON/BPV-1 cells were exposed to wt or recombinant VV, and harvested at 24 h. Cell lysates were prepared and partially purified by sucrose density gradient centrifugation and filtered through 1.2 ~tm and 0"2 Ixm filters. The filtered pellet from the sucrose gradient was applied to C127 cells. For the neutralization assay, the filtered pellet was first incubated with rabbit anti-BPV-1 serum at 1 : 100 for 1 h at 37 °C. BPV-1 particles were absorbed to C127 cells in DMEM medium for 2 h at 37 °C, then fetal bovine serum was added to a final concentration of 5%. Total RNA was extracted from cells after 12 h. Replication of BPV-1 DNA in C 127 cells is dependent on transcription of the E1 early gene (Lusky & Botchan, 1984) . E1 mRNA could be detected in C127 cells, 12 h after exposure of cells to synthetic BPV-1 virions purified from CON/BPV-1 cells infected with the L1/L2 VV recombinant, but not with particles from the same cells infected with the L1 VV or the L2 W recombinants alone (Fig, 4b) . mRNA corresponding to the E2, E6 or E 7 0 R F s was not detected at this early time point; experiments at later time points were precluded as there was low level contamination of the VLP preparations with VV recombinants. To show that E1 mRNA transcription was not a result of low efficiency uptake of BPV-1 plasmid DNA by C127 cells, we tested for inhibition of infection of C127 cells by the synthetic BPV-1 virions, using a rabbit polyvalent antiserum (Dako) raised against disrupted BPV-1 capsids. Prior incubation of synthetic BPV-1 virions with this antiserum, but not with a rabbit polyvalent antiserum specific for the E6 protein of HPV-16, blocked infection of the cells, as judged by failure to detect E1 mRNA. We conclude that the BPV-1 DNA from which E1 mRNA was transcribed was linked to the BPV-I L1 protein, presumably in the form of intact BPV-1 virions: similar assays have been used to examine for 'infectious' HPV-11 particles isolated from clinical lesions (Bonnez et al., 1992) using a nude mouse model. Production of PV virions which are able to be taken up by cells in vitro with resultant transcription of early genes should allow characterization of PV receptor(s) on epithelial cells, and evaluation of strategies for immunizing against infection with animal and human PVs. 
